


What is claimed is ;


1. A cell activator comprising a glycosphingolipid having a structure represented by the following formula (1):

formula (1)



wherein R<sup>1</sup> represents the following formula (1-1):

formula (1-1)




wherein R<sup>3</sup> represents alkyl or alkenyl and R<sup>4</sup> represents alkyl; and

R<sup>2</sup> represents hydrogen, or  $\alpha$ -galactose,  $\alpha$ -glucose,  $\alpha$ -mannose,  $\alpha$ -glucosamine,  $\beta$ -glucosamine or a combination thereof.


2. A cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)




wherein R<sup>5</sup> represents R<sup>51</sup>, R<sup>52</sup>, R<sup>53</sup>, R<sup>54</sup>, R<sup>55</sup>, R<sup>56</sup>, R<sup>57</sup>, R<sup>58</sup>, R<sup>59</sup>, R<sup>70</sup>, R<sup>71</sup>, R<sup>72</sup>, R<sup>73</sup>, R<sup>74</sup>, R<sup>75</sup>, R<sup>76</sup>, R<sup>77</sup>, or R<sup>78</sup>; and R<sup>6</sup> represents hydrogen, R<sup>62</sup>, R<sup>63</sup>, R<sup>64</sup>, or R<sup>65</sup>:


R<sup>51</sup> :




R<sup>52</sup> :




R<sup>53</sup> :




R<sup>54</sup> :




R<sup>55</sup> :




R<sup>56</sup> :




R<sup>57</sup> :




R<sup>58</sup> :




R<sup>59</sup> :




R<sup>70</sup> :




R<sup>71</sup> :




R<sup>72</sup> :




R<sup>73</sup> :




R<sup>74</sup> :




R<sup>75</sup> :




R<sup>76</sup> :




R<sup>77</sup> :




R<sup>78</sup> :




R<sup>62</sup> :




R<sup>64</sup> :



R<sup>63</sup> :



R<sup>65</sup> :



3. A method of activating NKT cell which comprises administering the cell activator according to claim 1 to a mammal.

4. A method of activating NKT cell which comprises administering the cell activator according to claim 2 to a mammal.

5. A method of accelerating IL-4 production which comprises administering the cell activator according to claim 1 to a mammal.

6. A method of accelerating IL-4 production which comprises administering the cell activator according to claim 2 to a mammal.

7. A method of accelerating IFN- $\gamma$  production which comprises administering the cell activator according to claim 1 to a mammal.

8. A method of accelerating IFN- $\gamma$  production which comprises administering the cell activator according to claim 2 to a mammal.

9. A method of activating dendritic cell which comprises administering the cell activator according to claim 1 to a mammal.

10. A method of activating dendritic cell which comprises administering the cell activator according to claim 2 to a mammal.

11. A method of accelerating IL-12 production which comprises administering the cell activator according to claim 1 to a mammal.

12. A method of accelerating IL-12 production which comprises administering the cell activator according to claim 2 to a mammal.

13. A method of accelerating IL-10 production which comprises administering the cell activator according to claim 1 to a mammal.

14. A method of accelerating IL-10 production which comprises administering the cell activator according to claim 2 to a mammal.

15. A method of activating NK cell which comprises administering the cell activator according to claim 1 to a mammal.

16. A method of activating NK cell which comprises administering the cell activator according to claim 2 to a mammal.

17. A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 1 to a mammal.

18. A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 2 to a mammal.

19. A method for treatment or prophylaxis of allergy comprises

administering the cell activator according to claim 1 to a mammal.

20. A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 2 to a mammal.

21. A method of enhancing resistance to infection which comprises administering the cell activator according to claim 1 to a mammal.

22. A method of enhancing resistance to infection which comprises administering the cell activator according to claim 2 to a mammal.

23. A method of inhibiting viral activity which comprises administering the cell activator according to claim 1 to a mammal.

24. A method of inhibiting viral activity which comprises administering the cell activator according to claim 2 to a mammal.

25. A method of accelerating IL-6 production which comprises administering the cell activator according to claim 1 to a mammal.

26. A method of accelerating IL-6 production which comprises administering the cell activator according to claim 2 to a mammal.

27. A method of accelerating NO production which comprises administering the cell activator according to claim 1 to a mammal.

28. A method of accelerating NO production which comprises administering the cell activator according to claim 2 to a mammal.